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Mycobacterium tuberculosis enoyl-acyl-ACP reductase (InhA) has been demonstrated to be the primary target
of isoniazid (INH). Recently, it was postulated that M. tuberculosis dihydrofolate reductase (DHFR) is also a
target of INH, based on the findings that a 4R-INH-NADP adduct synthesized from INH by a nonenzymatic
approach showed strong inhibition of DHFR in vitro, and overexpression ofM. tuberculosis dfrA inM. smegmatis
conferred a 2-fold increase of resistance to INH. In the present study, a plasmid expressingM. tuberculosis dfrA
was transformed into M. smegmatis and M. tuberculosis strains, respectively. The transformant strains were
tested for their resistance to INH. Compared to the wild-type strains, overexpression of dfrA in M. smegmatis
andM. tuberculosis did not confer any resistance to INH based on the MIC values. Similar negative results were
obtained with 14 other overexpressed proteins that have been proposed to bind some form of INH-NAD(P)
adduct. An Escherichia coli cell-based system was designed that allowed coexpression of both M. tuberculosis
katG and dfrA genes in the presence of INH. The DHFR protein isolated from the experimental sample was not
found bound with any INH-NADP adduct by enzyme inhibition assay and mass spectroscopic analysis. We also
used whole-genome sequencing to determine whether polymorphisms in dfrA could be detected in six INH-
resistant clinical isolates known to lack mutations in inhA and katG, but no such mutations were found. The
dfrA overexpression experiments, together with the biochemical and sequencing studies, conclusively demon-
strate that DHFR is not a target relevant to the antitubercular activity of INH.
In 1952, isoniazid (INH) was discovered to have bactericidal
activity against Mycobacterium tuberculosis (4). Since then, it
has been used as a potent front-line drug against tuberculosis
(5). The mechanism of action of INH has been studied for
more than 50 years. Through lipid profiling, INH was found to
inhibit mycolic acid biosynthesis in M. tuberculosis (28). In
addition, the INH-induced inhibition of mycolic acid biosyn-
thesis was demonstrated to correlate with the bactericidal ac-
tivity of INH (21). Further analysis of the lipids of INH-treated
M. tuberculosis indicated that the elongation of fatty acids
beyond C26 was inhibited, which suggested that the target of
INH is an enzyme in fatty acid elongation (20).
INH is a prodrug that must first be activated by KatG, an
endogenous catalase/peroxidase (29). The mode of INH action
remained unclear until an INH-NAD adduct was identified as
the bound inhibitor in the active site of InhA, the enoyl-acyl
ACP reductase involved in long-chain fatty acid biosynthesis,
by protein crystallography (18). It was hypothesized that KatG
cleaves the hydrazide on INH to an isonicotinoyl radical, which
then reacts with NAD to form an adduct that binds to and
inhibits InhA (23). The crystal structure of InhA bound with
the adduct indicates that an isonicotinoyl moiety was co-
valently attached to the 4-position of the nicotinamide ring of
NAD cofactor in an S configuration. The chemical structure of
the INH-NAD adduct was found to be consistent with the
molecular weight obtained by the mass analysis (18). Later
studies demonstrated that INH-NAD adduct could be gener-
ated by a KatG-catalyzed oxidation in the presence of NAD
(13, 27), which strongly inhibits InhA (Ki  5 nM) to block
mycolic acid biosynthesis (18, 25, 17).
Mutations within the protein-coding and promoter regions
of inhA are frequently observed in clinical isolates resistant to
INH (7, 22). An S94A mutation in InhA, which was originally
identified in an INH-resistant M. smegmatis strain, was later
found in three M. tuberculosis clinical isolates that conferred
resistance to both INH and ethionamide (ETH) (16, 3). The
S94A allele of inhA has been transferred into M. tuberculosis by
a specialized linkage transduction, which was sufficient to con-
fer 5-fold resistance to INH (25). Moreover, overexpression of
inhA in M. tuberculosis was found to confer10-fold resistance
to INH (12). These genetic observations support that InhA is
the primary target of INH.
Although genetic and biochemical studies have provided
convincing evidence that InhA is the primary target of INH,
other putative targets of INH have also been proposed (15,
24). Recently, 17 proteins other than InhA were identified
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from M. tuberculosis lysate that could tightly bind to an affinity
matrix derived from INH-NADP or INH-NAD adducts by
proteomic analysis (1). Among these proteins, M. tuberculosis
dihydrofolate reductase (DHFR) was shown to be strongly
inhibited by an INH-NADP adduct in vitro (Ki app  1 nM) in
a separate study (2). This INH-NADP adduct was synthesized
by incubating INH and NADP in the presence of Mn(III) as
a catalyst. The crystal structure of the complex indicated that
an acyclic 4R INH-NADP adduct was selectively bound in the
active site of DHFR. In addition, overexpression of dfrA in
M. smegmatis caused a 2-fold increase of resistance to INH
compared to the wild-type (2). These observations were
taken to suggest that M. tuberculosis DHFR is also a target
of INH (1, 2).
There are several observations which conflict with the pro-
posal that DHFR might be a target of INH. First, the MIC
difference (2-fold) between the dfrA overexpressed M. smeg-
matis strain and the wild-type strain is not significant compared
to the error of this type of experiment. Second, dfrA has not
been clearly shown to be essential to M. tuberculosis. Although
it is an essential gene for nucleotide biosynthesis in many other
organisms (10, 6), disruption of dfrA by transposon mutagen-
esis was found not to attenuate M. tuberculosis infection in
mice (19). Third, the endogenous formation of the 4R INH-
NADP adduct by KatG catalysis has not been demonstrated.
To determine whether M. tuberculosis DHFR is a molecular
target of INH, we investigated (i) whether overexpression of
dfrA under relevant conditions confers resistance to INH in M.
smegmatis and M. tuberculosis, (ii) whether the INH-NADP
adduct is an activated INH product generated by KatG catal-
ysis inside the cell, and (iii) whether mutations in dfrA could be
observed in INH-resistant clinical isolates.
MATERIALS AND METHODS
Cloning, expression, and purification. The M. tuberculosis dfrA and katG genes
were cloned as previously described (2). The plasmids of M. tuberculosis katG
and dfrA were singly and doubly transformed into E. coli BL21(DE3) (EMD
Bioscience, catalog no. 69387-3). The strain containing plasmids of katG and
dfrA was cultured in LB-Miller medium containing 50 g of kanamycin/ml and 50
g of carbenicillin/ml at 37°C until the optical density (OD) at 600 nm reached
0.5. Expression of both genes was carried out by induction for 20 h at 18°C by
the addition of 1 mM IPTG (isopropyl--D-thiogalactopyranoside). At the
same time of induction, 100 g of INH/ml was also added to the culture. The
same protocol was used for the strain containing just the dfrA plasmid.
Recombinant M. tuberculosis DHFR was purified according to a previously
described method (2).
DHFR and KatG enzymatic activity assay. All assays were carried out on a
Cary 100 Bio Spectrophotometer at 25°C. DHFR assays are performed by mon-
itoring the oxidation of NADPH and reduction of dihydrofolate (DHF) at 340
nm. Reactions were initiated by adding DHFR (10 nM) to assay mixtures con-
taining NADPH (10 M), DHF (4.5 M), and phosphate buffer (pH 7.5, 50
mM). The KatG activity was assayed as previously described (31).
Mass spectroscopy analysis. Purified DHFR was heated for 60 s at 100°C.
After the heat treatment, denatured enzyme was separated by filtration, using a
Centricon (cutoff, 3 kDa). The filtrate was used for mass analysis. The matrix-
assisted laser desorption ionization (MALDI) mass spectrometry experiment was
carried out on an ABI Voyager-DE STR.
Crystallization of InhA in complex with INH-NAD adduct. Crystallization was
accomplished by the hanging-drop vapor diffusion method. M. tuberculosis InhA
in complex with INH-NAD was cocrystallized in hanging droplets containing 2 l
of protein solution at 10 mg/ml and with 2 l of buffer (12% 2-methyl-2,4-
pentanediol, 4% dimethyl sulfoxide, 0.1 M HEPES, and 0.025 M sodium citrate)
at 16°C in Linbro plates against 1 ml of the same buffer. Diamond shaped protein
crystals formed 4 days later.
T7-based expression system for mycobacteria. (i) Construction of M. smegma-
tis expression strain, mc24517. pT7Pol26 was digested with BamHI to excise the
RNA polymerase gene of bacteriophage T7. The 2.7-kb BamHI DNA fragment
was ligated to BamHI-digested pSD26 plasmid, and the orientation was con-
firmed by digestion with the appropriate restriction enzymes. The DNA fragment
of an acetamidase promoter fused to T7 polymerase was then cloned into
pMV306, to generate pYUB1232. The expression strain mc24517 was obtained
after electroporating pYUB1232 into M. smegmatis mc2155.
(ii) Construction of expression plasmids. pYUB1062, the parental expression
plasmid, was constructed by combining the NarI/SspI DNA fragment (948 bp)
from pET30a plasmid and the NarI/EcoRV DNA fragment (4,026 bp) of
pMV206. Shuttle vector pYUB1062 contains an oriE for replication in E. coli,
oriM for replication in mycobacteria, a hygromycin cassette for antibiotic selec-
tion, a T7 promoter/terminator, and a histidine tag region for the purification of
overproduced protein. The various M. tuberculosis genes were cloned into
pYUB1062 using NdeI or NcoI as the upstream site and an appropriate down-
stream site.
(iii) Expression of INH-NAD- or INH-NADP-binding proteins from M. tuber-
culosis. M. smegmatis mc24517 cells were transformed with plasmids expressing
INH-NAD- or INH-NADP-binding protein of M. tuberculosis. A single bacterial
colony was grown in all cases at 37°C to an A600 of 0.6 to 0.8 in Middlebrook 7H9
broth medium supplemented with 0.2% Tween 80, 0.05% glycerol, kanamycin
(20 g/ml), and hygromycin B (100 g/ml). Cell cultures were diluted 1:100 in 50
ml of the same liquid medium and cells were grown to mid-exponential phase
(A600  0.5 to 0.6) at 37°C at 120 rpm before induction with acetamide. The
bacterial cultures were divided into equal volumes, and 0.2% (wt/vol) acetamide
was added to the one of the aliquots (the other aliquot was used as a control).
Expression of protein was determined after 6 h of induction by analyzing the
cell-free protein extract by 10 to 20% SDS-PAGE.
MIC determination.M. smegmatis cells expressing the M. tuberculosis proteins
were grown to an OD of 0.6 and then induced with 0.2% acetamide for6 h until
the OD reached 1.0. The cells were then diluted by 105-fold and incubated in
200 l of 7H9 medium containing INH (0, 0.6, 1.2, 4.7, 9.4, 18.6, 37.5, 75, 150,
and 300 g/ml) in a 96-well plate. The plates were incubated at 37°C and
observed after 72 h. The MIC was determined as the concentration of drug at
which no visible growth was observed. MICs for M. tuberculosis strains were
determined by using an MTT assay (14). The concentrations of INH tested were
0, 0.015, 0.03, 0.06, 0.12, 0.24, 0.48, 0.96, 1.92, and 3.84 g/ml.
Sequencing of clinical isolates. Six INH-resistant clinical isolates (strains 5071,
5072, 5297, 5324, 5358, and 5400) were obtained for whole-genome sequencing.
The clinical isolates were collected from Mexico between 1991 and 1996 by the
Laboratory of Clinical Microbiology, Instituto Nacional de Ciencias Me´dicasy
Nutricio´n Salvador Zubira´n, Mexico City, under an IRB-approved protocol. Five
of the six strains were genotyped as belonging to SNP cluster group SCG_3b,
whereas strain 5358 belongs to the M. bovis family based on spoligotyping. MICs
for INH ranged from 0.2 to 8.0 g/ml compared to 0.03 g/ml for H37Rv.
Genomic DNA was extracted by using a CTAB (cetyltrimethylammonium
bromide) protocol as previously described (11). The DNA library was con-
structed by using a genomic DNA sample preparation kit (Illumina). The sample
was first fragmented by using a nebulization technique. Then, the double-
stranded DNA fragments comprised of 3 or 5 overhangs were converted into
blunt ends, using T4 DNA polymerase and Klenow enzyme. Klenow 3-to-5
exonuclease minus was used to add an “A” base to the phosphorylated 3 blunt
end of the DNA fragments so that the fragments could be ligated to the adaptors,
which have a single “T” base overhang at their 3 end. The ligated DNA was then
size selected on a 2% agarose gel. DNA fragments of300 bp were excised from
the preparative portion of the gel. DNA was then recovered by using a Qiagen
gel extraction kit and PCR amplified to produce the final DNA library. A total
of 5 pmol of DNA from each strain was loaded onto a different lane of the
sequencing chip (eight lanes total), and the clusters were generated on the cluster
generation station of a Genome Analyzer II using the Illumina Cluster genera-
tion kit. Bacteriophage X174 DNA was used as a control.
The sequencing reaction was run for 36 cycles (tagging, imaging, and cleavage
of one terminal base at a time), and four images of each tile on the chip were
taken in different wavelengths for exciting each base-specific fluorophore. Image
analysis and base-calling were done by using v0.3 of the Illumina GA Pipeline
software.
The 36 bp reads that were generated for each strain were mapped (aligned)
against H37Rv as a reference sequence (or M. bovis in the case of strain 5358,
which was the closest reference strain by spoligotyping). Apparent differences (at
sites where the consensus base from overlapping reads differed from the ex-
pected base in the reference sequence), along with sites where coverage was low
or observed bases were heterogeneous, were identified, and local contig-building











was used to resolve them into SNPs versus indels, based on alignment to the
corresponding region in the reference genome.
RESULTS
Overexpression of dfrA does not confer resistance to INH.
The most direct evidence to support that DHFR is a target of
INH comes from the observation that overexpression of dfrA in
M. smegmatis conferred a 2-fold increase in resistance to INH
(2). Therefore, we first reexamined whether overexpression of
this protein using a strong promoter in M. smegmatis would
lead to increased resistance to INH. Use of cosmids harboring
a gene on a multicopy plasmid along with its native promoter
might be a desired approach to overexpress putative targets.
However, this can result in a failure to observe overexpression
whether the expression of the protein is from a tightly regu-
lated promoter. To eliminate the promoter-specific effect, a
novel T7-based expression system was developed for the effi-
cient expression of proteins in mycobacteria. In brief, an M.
smegmatis strain (mc24517) was generated by integrating a
plasmid expressing the T7 polymerase under the acetamidase-
inducible promoter into the genome at the mycobacteriophage
L5 attachment site. M. tuberculosis genes were cloned under
the T7 promoter on a separate episomal plasmid pYUB1062.
Protein expression was induced by the addition of 0.2% acet-
amide. To ensure overexpression of dfrA and inhA, protein
lysates were analyzed on SDS gels, and a high level of expres-
sion was observed within 6 h of induction as a distinct band
corresponding to the expected size compared to the uninduced
control (Fig. 1). The strains overexpressing dfrA (mc25097) and
inhA (mc25089) were then tested for their susceptibility to INH
and ETH and the results obtained are summarized in Table 1.
The MIC for the inhA overexpression strain mc25089 increased
more than 60-fold to 300 g/ml for INH, compared to the
wild-type strain. In contrast to InhA, we did not observe any
increase in MIC for mc25097, the strain overexpressing DHFR,
which had been reported to confer 2-fold resistance to INH
when induced in M. smegmatis with an acetamidase promoter
(2). Other than DHFR and InhA, 16 additional proteins from
M. tuberculosis were identified in a previous study (1) that
bound to an INH-NAD or INH-NADP adduct in vitro. We
applied the same T7 promoter system to successfully overex-
press 14 of these genes in M. smegmatis, but none of them
could confer resistance to INH or ETH (Table 1). Since this
analysis was done in liquid culture, we also tested the ability of
the strains to grow on plates with two times the MIC for INH.
As shown in Fig. 2, the M. smegmatis strain containing the
overexpressed DHFR (mc25072) failed to grow on an INH-
containing plate, while the strain overexpressing InhA
(mc25071) showed complete resistance. To find out whether
DHFR was indeed expressed, the strain containing the over-
FIG. 1. Overexpression of the proteins in M. smegmatis confirmed
by SDS-PAGE analysis. Lanes: M, marker; 1, vector; 2, Rv0155
(PntAA, 40 kDa); 3, Rv1484 (InhA, 29.5 kDa); 4, Rv2763c (DfrA, 17.4
kDa); 5, Rv1996 (34.9 kDa); 6, Rv2623 (32.7 kDa); 7, Rv2766c
(FabG5, 30.8 kDa); 8, Rv2858 (AldC, 50 kDa); 9, uninduced Rv2763c
(DfrA); 10, induced Rv2763c (DfrA).
TABLE 1. MICs determined in 7H9 broth by serial dilution
method after overexpressing the INH-NAD binding proteins




None (mc24517 parental strain) 4.7 9.4
Rv1484 (InhA) 300 150
Rv2763c (DfrA) 4.7 9.4
Rv3248c (SahH) 4.7 9.4
Rv0753c (MmsA) 4.7 9.4
Rv1187 (RocA) 4.7 9.4
Rv0155 (PntAA) 4.7 9.4
Rv2623 (universal stress protein) 4.7 9.4
Rv1996 (universal stress protein) 4.7 9.4
Rv0468 (FadB2) 4.7 9.4
Rv2691 (CeoB/TrkA) 4.7 9.4
Rv0091 (Mtn/Sah) NA NA
Rv2858c (AldC) 4.7 9.4
Rv1059 (unknown) 4.7 9.4
Rv0926c (unknown) 4.7 9.4
Rv3777 (probable oxidoreductase) 4.7 9.4
Rv2971 (probable oxidoreductase) NA NA
Rv2766 (FabG5) 4.7 9.4
Rv2671 (RibD) 4.7 9.4
a NA, not available (overexpression was not successful).
FIG. 2. Growth of the wild-type M. smegmatis strain and trans-
formed strains overexpressing DHFR or InhA on media containing the
known DHFR inhibitor trimethoprim (50 or 150 g/ml) or INH (10 or
120 g/ml).











expressed DHFR was plated on medium containing the known
DHFR inhibitor trimethoprim. Strain mc25072 (DHFR over-
expresser) was able to grow on medium containing 50 or 150
g of trimethoprim/ml. In contrast, the parental strain
mc25069 or the strain overexpressing InhA (mc25071) failed to
grow on trimethoprim-containing plates. One possible expla-
nation for the difference between our findings and those re-
ported previously (2) might be that the growth inhibition ex-
periment in the previous study was carried out at 30°C, which
is not optimal for growth, whereas the growth inhibition ex-
periments in our study were performed at 37°C. Our observa-
tion that the overexpression of M. tuberculosis InhA but not
DHFR confers resistance to INH and ETH in M. smegmatis
using this new expression system is consistent with InhA being
the primary target of INH and ETH. Even though DHFR has
been shown to bind an INH-NADP adduct in vitro, this phe-
nomenon is not sufficient to confer INH or ETH resistance in
mycobacterial cells.
A second overexpression experiment was conducted using
the H37Rv strain of M. tuberculosis, which is more disease
relevant, compared to M. smegmatis. The M. tuberculosis
H37Rv strain was transformed with the pMV261::dfrA plas-
mid. The MIC of INH for the M. tuberculosis strain overex-
pressing dfrA is identical to that of the wild-type H37Rv strain
(0.06 g/ml). On plates with three times the MIC for INH, no
growth of the M. tuberculosis strain overexpressing dfrA was
observed. In contrast, the M. tuberculosis strain overexpressing
inhA survived (Fig. 3), which is consistent with the previous
report that the MIC for M. tuberculosis overexpressing inhA
(1.0 g/ml) increased 20-fold compared to the wild-type
H37Rv strain (MIC  0.06 g/ml) (12). Therefore, similar to
what we observed in our M. smegmatis experiment, overexpres-
sion of dfrA did not prevent growth inhibition of M. tuberculosis
by INH, which genetically demonstrates that M. tuberculosis
DHFR is not a relevant target of INH.
INH-NADP adduct formation was not observed in an E.
coli-based activation system coexpressing katG and dfrA. In the
previous study, a synthetic INH-NADP adduct derived from
INH demonstrated strong inhibition of M. tuberculosis DHFR
in vitro (Ki app  1 nM) (2). However, the INH-NADP adduct
was synthesized by using an inorganic catalyst, Mn(III). Thus,
the yield of adduct generated from this approach might not
truly reflect an enzyme-mediated process inside the cell. To
better mimic the in vivo activation of INH, a cell-based acti-
vation system was designed to examine the KatG-catalyzed
adduct formation and the inhibition of DHFR by the adduct.
This E. coli-based activation system is similar to the one used
previously to activate the prodrugs ETH and protionamide
(PTH) (26). In this system, katG and dfrA were coexpressed in
E. coli in the presence of INH to investigate whether the
activated drug would inhibit DHFR. To construct this system,
katG and dfrA were cotransformed into the E. coli BL21(DE3)
strain and selected on 50 g of kanamycin and carbenicillin/ml.
The E. coli strain containing katG and dfrA genes was grown
and induced in the presence and absence of INH, respectively.
After the coexpression of both genes was confirmed by SDS-
PAGE, recombinant KatG and DHFR proteins were readily
purified.
Mass spectroscopy was used to determine whether DHFR
purified from the experimental sample was bound with any
inhibitor. We have previously applied mass spectroscopy to
identify the INH-NAD, ETH-NAD, and PTH-NAD adducts
bound to InhA (18, 26). Before the mass spectroscopic analy-
sis, the purified DHFR was concentrated and then denatured,
followed by filtration to separate small molecules from the
denatured protein. The MALDI mass spectrum of the filtrate,
which ranged between 200 and 1,200 Da, was carefully ana-
lyzed. We were not able to identify any compound that has a
molecular mass corresponding to an INH-NADP adduct. The
peaks shown on the spectrum most likely resulted from the
cofactor NADP and some small fragments of the protein.
An enzyme assay was performed to determine the activity of
purified DHFR. DHFR isolated from the experimental sample
was found to be fully active (specific activity of 12 mol mg	1
min	1) compared to the enzyme purified from expression in
the absence of INH. Since the acyclic 4R INH-NADP adduct
is extremely potent against DHFR in vitro, it would tightly bind
to DHFR if the adduct is indeed generated by KatG catalysis
inside the cell. However, both the activity assay result and the
mass analysis indicated that no detectable amount of the INH-
NADP adduct had bound to DHFR. The coexpressed KatG
from the same experimental sample was purified and assayed
for its activity in vitro. The specific catalase activity of isolated
KatG was 17 mol mg	1 min	1, a finding comparable to pub-
lished data (21 mol mg	1 min	1) (13), which confirmed that
the lack of the INH-NADP adduct did not result from the
absence of KatG activity. Therefore, the acyclic 4R INH-
NADP adduct is not an activated INH product generated by
KatG catalysis inside the E. coli cell-based system.
INH-NAD adduct was detected in the E. coli based activa-
tion system coexpressing katG and inhA. It has been shown
that KatG activates INH and catalyzes the formation of an
INH-NAD adduct in vitro (23, 27). In order to demonstrate
that this KatG-catalyzed INH-NAD adduct formation and its
inhibition of InhA can be reproduced in the E. coli-based
system, both katG and inhA were transformed into E. coli and
coexpressed in the presence of INH. InhA was rapidly purified
by a Ni-NTA affinity column, and an in vitro enzyme assay was
performed. InhA isolated from the experimental sample had

15% of the specific activity of InhA purified without the
addition of INH under the same assay condition. The bound
inhibitor was isolated by denaturing the InhA purified from the
experimental sample, and a 1 M concentration of the inhib-
itor led to complete inhibition of native InhA. The crystal
FIG. 3. Growth of M. tuberculosis H37Rv strains overexpressing
DHFR or InhA on media containing INH (0.2 g/ml) or kanamycin
(100 g/ml). Spots: A, pMV261::inhA (InhA overexpresser); B,
pMV261 (plasmid only); C to F, four independent transformants of
pMV261::dfrA (DHFR overexpresser).











structure of InhA in complex with the inhibitor was solved to
2.4-Å resolution. In the active site of InhA, an unbiased elec-
tron density map clearly indicated the presence of a modified
NAD with an isonicotinic-acyl group covalently attached to the
4-position of the nicotinamide ring in a 4S configuration, which
is consistent with the previously identified INH-NAD adduct
(18). This is the first time that the activation of INH by KatG
and the formation of the INH-NAD adduct has been demon-
strated in a whole-cell environment. This confirms that our E.
coli cell-based system is capable of activating the prodrug INH.
Absence of polymorphisms in dfrA in INH-resistant clinical
isolates. As an alternative approach to determining whether
DHFR might be a relevant target of INH, we used whole-
genome sequencing to determine whether mutations in dfrA
could be observed in INH-resistant clinical isolates. We se-
quenced the genomes of six clinical isolates that were INH
resistant but known not to have relevant mutations in inhA,
katG, or their promoters. The six strains were sequenced by
using an Illumina Genome Analyzer II (see Materials and
Methods). The depth of coverage (i.e., the number of reads
overlapping each site, averaged over the whole genome) was
36.9x to 49.4x for each strain, providing high confidence in the
final base calls. This method has been used successfully to
identify known and novel mutations associated with resistance
to INH, rifampin, pyrazinamide, kanamycin, ofloxacin, strep-
tomycin, etc., in many other strains sequenced in our lab.
Coding regions for the 17 putative INH-NADH-binding pro-
teins identified earlier (1) were searched for polymorphisms.
The 100-bp regions upstream of the operon containing each
gene were also searched for possible SNPs in the promoter
region that might affect expression level. None of the six clin-
ical isolates harbored any mutations in dfrA or its promoter
(Table 2). Furthermore, few nonsynonymous mutations were
found in any of the other 16 genes identified as potential
proteins that can bind an INH-NAD(P)H adduct. Strain 5358
showed the most mutations, due to its evolutionary distance
from the others (5358 belongs to the M. bovis family), but most
of the mutations in strain 5358 were also observed in the
genome for INH-sensitive M. bovis BCG, implying that they
are not responsible for INH resistance. The only sites where
there are potentially relevant differences (i.e., nonsynonymous
and not in BCG) are a 931-bp deletion of mtn in 5400,
aldC(T21A) in 5297, the a-64c promoter mutation upstream of
Rv1059, the 1-bp frameshift mutation in Rv1059 in 5297, and
Rv3777:P101A in 5297.
For completeness, other genes traditionally associated with
INH resistance were also searched, including katG, iniC, ndh,
ahpC, etc. (8), but no known mutations responsible for INH
resistance could be identified (Table 3). Two strains showed
mutations in katG (F129S in strain 5400 and G285V in strain
5324), and one strain has a mutation in efpA (Q513R in strain
5324). None of these mutations has been previously reported
in INH-resistant strains. The katG F129S mutation is located
at the dimer interface, and the katG G285V mutation is lo-
cated at the mouth of the active site entrance, so their effect on
INH activation is unclear. Mutations in mshA, which catalyzes
the first step in mycothiol biosynthesis, have also been linked
with INH and ETH resistance, but the N111S allele appears in
the Erdman strain, which is as susceptible to these drugs as
H37Rv (25a). Although the true cause of INH resistance in
these six strains remains undetermined, the lack of mutations
in dfrA and the 16 other putative INH-NAD(P)-binding pro-
teins suggests that they are unlikely to be targets of INH. We
also have sequenced the dfrA gene in six additional M. tuber-
culosis strains known to be INH-resistant but with no known
relevant mutations. None of these had a mutation in the dfrA
gene. Consistent with our findings, a recent large-scale screen-
ing of 127 INH-resistant M. tuberculosis isolates from Singa-
pore by PCR sequencing also revealed no mutations within
dfrA (9).
TABLE 2. Mutations in genes identified as potential INH-NAD(P) bindersa
Protein
Mutation in strain:
5071 5072 5297 5324 5358 5400 M. bovis BCG
Rv2763c/dfrA None None None None None None None
Rv3248c/sahH None None None None None None None
Rv0753c/mmsA None None None None None None None
Rv1187/rocA None None None None None None None
Rv0155/pntAa A274A None None None None None None
Rv2623 None None None None None None None
Rv1996 None None None None None None None
Rv0468/fadB2 None None None None L87L None L87L
Rv2691/ceoB T117A T117A T117A T117A T117A T117A T117A
Rv0091/mtn None A155P None Q174Q None 931-bp deletion None
Rv2858c/aldC None None T21A None P77P None P77P
Rv1059 a-64cb 1-bp deletion in P99 None None None None None
Rv3777 None None P101A None None None None
Rv3777 V160A V160A V160A V160A V160A V160A V160A
Rv3777 L63L L63L L63L L63L L63L L63L L63L
Rv0926c None None None None None None None
Rv2766c/fabG5 None None None None None None None
Rv2671/ribD None None None None None None None
Rv2971 None None None None N152H None N152H
a Argyrou et al. (1). Mutations are indicated relative to the amino acid in the H37Rv reference sequence. Mutations that are shared with M. bovis BCG are assumed
not to cause isoniazid resistance.
b Single nucleotide polymorphism in promoter region.












To validate a target of a bactericidal drug, it is necessary to
show that binding of the drug to the putative target causes
inhibition of biological activity, which leads to the death of the
cell. In the case of INH, it is more complicated to elucidate its
mechanism of action since INH is a prodrug. It is necessary to
not only demonstrate that the putative target is relevant to the
bactericidal activity of INH but also show how the active form
of INH inhibits the target protein. It has recently been postu-
lated that M. tuberculosis DHFR might be a target of INH,
mainly based on two independent observations: (i) a 4R INH-
NADP adduct, synthesized by a nonenzymatic approach,
showed strong inhibition of DHFR in vitro; and (ii) overex-
pression of dfrA in M. smegmatis conferred resistance to INH
(2). However, the 4R INH-NADP adduct has not been dem-
onstrated to be generated as a product of INH inside the cell
by KatG activation. By coexpressing katG and dfrA genes in E.
coli cells in the presence of INH, we showed that the DHFR
protein isolated from the experimental sample was not bound
with the INH-NADP adduct. This demonstrates that the 4R
INH-NADP adduct is not generated by KatG catalysis. In
contrast, KatG has been shown to generate the 4S isomer of
INH-NAD endogenously, which has been shown to bind to the
active site of InhA (18). Thus far, KatG is the only identified
activator of INH, and it is very unlikely that INH could be
activated by another unknown protein to form the INH-NADP
adduct in M. tuberculosis. Therefore, we conclude that the
synthetic INH-NADP adduct is not biologically relevant to
INH inhibition. We also examined the ability of overexpressed
dfrA to confer resistance to INH in M. smegmatis and M.
tuberculosis. We found that at 37°C, overexpression of dfrA in
both M. smegmatis and M. tuberculosis did not confer any
resistance to INH. Although dfrA overexpression was previ-
ously found to confer low-level resistance in M. smegmatis (2),
that experiment was carried out at a temperature (30°C) which
is not optimal for cell growth. If DHFR were a target of INH,
then it might be expected that mutations might occur in dfrA in
INH-resistant clinical isolates lacking mutations in inhA or
katG. Although mutations in inhA or katG and their promoters
account for most cases of resistance to INH, the remaining 10
to 25% of cases must have mutations in other genes relevant to
INH toxicity (30). In the present study, we sequenced clinical
isolates selected from this subpopulation but did not observe
any mutations in dfrA. Taken together, these pieces of evi-
dence refute the hypothesis that DHFR or any of the other
INH-NAD(P)-binding proteins is a biologically relevant target
for INH in M. tuberculosis.
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